Acquisitions - Kinnate Acquisition (Details) - USD ($) $ / shares in Units, $ in Thousands |
1 Months Ended | ||
|---|---|---|---|
Apr. 30, 2024 |
Mar. 31, 2026 |
Dec. 31, 2025 |
|
| Asset Acquisition | |||
| Exarafenib milestone contingent consideration | $ 3,704 | $ 3,600 | |
| CVR Agreement | Kinnate CVR holders | |||
| Asset Acquisition | |||
| Exarafenib milestone contingent consideration | $ 3,700 | $ 3,600 | |
| Kinnate | |||
| Asset Acquisition | |||
| Asset acquisition, share price (in dollars per share) | $ 2.5879 | ||
| Total purchase consideration | $ 126,400 | ||
| Net proceeds from specified assets (as a percent) | 85.00% | ||
| Kinnate | CVR Agreement | Kinnate CVR holders | |||
| Asset Acquisition | |||
| Percentage share from potential milestone | 100.00% | ||
| Cash received from milestone payments | $ 30,500 |